propranolol has been researched along with Marfan Syndrome in 20 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Marfan Syndrome: An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 9.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| " This focused review emphasizes the results of clinical trials using β-blocker, losartan potassium, and irbesartan in patients with Marfan syndrome and comments briefly on mechanisms of aortic remodeling, including fibrosis and transforming growth factor β signaling." | 9.01 | Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review. ( Eagle, KA; Hofmann Bowman, MA; Milewicz, DM, 2019) |
| "Twenty-five patients, 16 men and 9 women, 5-59 years of age with the Marfan syndrome and cardiac complications were started on propranolol over a 6-year period." | 7.65 | Prophylactiv use of propranolol in the Marfan syndrome to prevent aortic dissection. ( McKusick, VA; Ose, L, 1977) |
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 5.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| " This focused review emphasizes the results of clinical trials using β-blocker, losartan potassium, and irbesartan in patients with Marfan syndrome and comments briefly on mechanisms of aortic remodeling, including fibrosis and transforming growth factor β signaling." | 5.01 | Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review. ( Eagle, KA; Hofmann Bowman, MA; Milewicz, DM, 2019) |
| "Based on only one, low-quality RCT comparing long-term propranolol to no treatment in people with Marfan syndrome, we could draw no definitive conclusions for clinical practice." | 4.95 | Beta-blockers for preventing aortic dissection in Marfan syndrome. ( Koo, HK; Lawrence, KA; Musini, VM, 2017) |
| "Twenty-five patients, 16 men and 9 women, 5-59 years of age with the Marfan syndrome and cardiac complications were started on propranolol over a 6-year period." | 3.65 | Prophylactiv use of propranolol in the Marfan syndrome to prevent aortic dissection. ( McKusick, VA; Ose, L, 1977) |
| "Marfan's syndrome is a connective tissue disorder inherited as an autosomal dominant disorder." | 2.45 | Marfan syndrome: a study of a Nigerian family and review of current cardiovascular management. ( Ekure, EN; Oke, DA; Onakoya, AO, 2009) |
| "Pregnancy in the Marfan syndrome is associated with two primary problems: potential catastrophic aortic dissection and the risk for having a child with the syndrome." | 2.39 | Cardiovascular problems in pregnant women with the Marfan syndrome. ( Elkayam, U; Mehra, A; Ostrzega, E; Shotan, A, 1995) |
| "A recent, prospective randomized trial has suggested that long-term use of prophylactic beta-adrenergic blocking agents may slow the rate of aortic dilation in those patients with Marfan's syndrome exhibiting evidence of existing dilation." | 1.30 | Blunted fetal response to vibroacoustic stimulation following chronic exposure to propranolol. ( Bentolila, E; Sherer, DM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, LH | 1 |
| Lin, SM | 1 |
| Lin, DS | 1 |
| Chen, MR | 1 |
| Koo, HK | 1 |
| Lawrence, KA | 1 |
| Musini, VM | 1 |
| Habashi, JP | 2 |
| MacFarlane, EG | 1 |
| Bagirzadeh, R | 1 |
| Bowen, C | 1 |
| Huso, N | 1 |
| Chen, Y | 1 |
| Bedja, D | 2 |
| Creamer, TJ | 1 |
| Rykiel, G | 1 |
| Manning, M | 1 |
| Huso, D | 1 |
| Dietz, HC | 2 |
| Hofmann Bowman, MA | 1 |
| Eagle, KA | 1 |
| Milewicz, DM | 1 |
| Elshershari, H | 1 |
| Harris, C | 1 |
| Ekure, EN | 1 |
| Onakoya, AO | 1 |
| Oke, DA | 1 |
| Chiu, HH | 1 |
| Wu, MH | 1 |
| Wang, JK | 1 |
| Lu, CW | 1 |
| Chiu, SN | 1 |
| Chen, CA | 1 |
| Lin, MT | 1 |
| Hu, FC | 1 |
| Bayles, J | 1 |
| Yetman, AT | 1 |
| Bornemeier, RA | 1 |
| McCrindle, BW | 1 |
| Judge, DP | 1 |
| Holm, TM | 1 |
| Cohn, RD | 1 |
| Loeys, BL | 1 |
| Cooper, TK | 1 |
| Myers, L | 1 |
| Klein, EC | 1 |
| Liu, G | 1 |
| Calvi, C | 1 |
| Podowski, M | 1 |
| Neptune, ER | 1 |
| Halushka, MK | 1 |
| Gabrielson, K | 1 |
| Rifkin, DB | 1 |
| Carta, L | 1 |
| Ramirez, F | 1 |
| Huso, DL | 1 |
| Elkayam, U | 1 |
| Ostrzega, E | 1 |
| Shotan, A | 1 |
| Mehra, A | 1 |
| Shores, J | 1 |
| Berger, KR | 1 |
| Murphy, EA | 1 |
| Pyeritz, RE | 2 |
| Tahernia, AC | 1 |
| Sherer, DM | 1 |
| Bentolila, E | 1 |
| Ose, L | 1 |
| McKusick, VA | 3 |
| Siggers, DC | 1 |
| Yin, FC | 1 |
| Brin, KP | 1 |
| Ting, CT | 1 |
| Cola, LM | 1 |
| Lavin, JP | 1 |
| Murdoch, JL | 2 |
| Walker, BA | 1 |
| Halpern, BL | 2 |
| Kuzma, JW | 1 |
| Char, F | 1 |
| Horton, WB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome[NCT00651235] | Phase 2 | 44 participants (Anticipated) | Interventional | 2007-02-28 | Recruiting | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| Thoracic Aortic Dilatation Syndromes - Diagnostic, Incidences, Morbidity, Mortality and Socioeconomical Observations.[NCT02111668] | 120 participants (Actual) | Observational [Patient Registry] | 2013-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for propranolol and Marfan Syndrome
| Article | Year |
|---|---|
Beta-blockers for preventing aortic dissection in Marfan syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aortic Dissection; Humans; Marfan Syndrome; Middle A | 2017 |
Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Thor | 2019 |
Marfan syndrome: a study of a Nigerian family and review of current cardiovascular management.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Child; Child, Preschool; Fe | 2009 |
Cardiovascular problems in pregnant women with the Marfan syndrome.
Topics: Delivery, Obstetric; Female; Genetic Counseling; Humans; Labor, Obstetric; Marfan Syndrome; Pregnanc | 1995 |
Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and beta-blockers.
Topics: Adolescent; Aortic Diseases; Auscultation; Child; Child, Preschool; Dilatation, Pathologic; Echocard | 1993 |
4 trials available for propranolol and Marfan Syndrome
| Article | Year |
|---|---|
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic | 2013 |
Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aorta; Atenolol; | 2005 |
Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome.
Topics: Adolescent; Adult; Aorta; Aortic Aneurysm; Aortic Dissection; Aortic Valve Insufficiency; Dilatation | 1994 |
Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and beta-blockers.
Topics: Adolescent; Aortic Diseases; Auscultation; Child; Child, Preschool; Dilatation, Pathologic; Echocard | 1993 |
12 other studies available for propranolol and Marfan Syndrome
| Article | Year |
|---|---|
Losartan in combination with propranolol slows the aortic root dilatation in neonatal Marfan syndrome.
Topics: Drug Therapy, Combination; Fibrillin-1; Humans; Infant, Newborn; Losartan; Male; Marfan Syndrome; Mu | 2018 |
Oxytocin antagonism prevents pregnancy-associated aortic dissection in a mouse model of Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Dissection; Disease Models, Animal; Female; Hydr | 2019 |
Paternal fibrillin-1 mutation transmitted to an affected son with neonatal marfan syndrome: the importance of early recognition.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Dilatation, Pathologic; | 2014 |
Sounding the alarm. If undetected, Marfan syndrome can be a silent killer.
Topics: Adrenergic beta-Antagonists; Adult; Aortic Aneurysm; Aortic Dissection; Chest Pain; Female; Humans; | 2002 |
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta; Ao | 2006 |
Blunted fetal response to vibroacoustic stimulation following chronic exposure to propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Female; Fetal Monitoring; Heart Rate, Fetal; Humans; Marfan Synd | 1998 |
Prophylactiv use of propranolol in the Marfan syndrome to prevent aortic dissection.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aorta, Thoracic; Aortic Aneurysm; Child, Preschool; | 1977 |
Marfan syndrome treated with propranolol.
Topics: Female; Humans; Marfan Syndrome; Middle Aged; Propranolol; Radiography | 1975 |
Arterial hemodynamic indexes in Marfan's syndrome.
Topics: Adult; Aorta; Blood Flow Velocity; Cardiac Catheterization; Female; Hemodynamics; Humans; Male; Marf | 1989 |
Pregnancy complicated by Marfan's syndrome with aortic arch dissection, subsequent aortic arch replacement and triple coronary artery bypass grafts.
Topics: Adult; Aorta, Thoracic; Aortic Aneurysm; Aortic Dissection; Cesarean Section; Coronary Artery Bypass | 1985 |
Life expectancy and causes of death in the Marfan syndrome.
Topics: Adolescent; Adult; Age Factors; Aged; Aortic Diseases; Cardiovascular Diseases; Child; Female; Human | 1972 |
A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment.
Topics: Adolescent; Adult; Aortic Aneurysm; Aortic Rupture; Child; Electrocardiography; Female; Follow-Up St | 1971 |